

DAFTAR PUSTAKA

1. Clark RA, Marin TS, Berry NM, Atherton JJ, Foote JW, Koczwara B. Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment. *Cardio-Oncology*. 2017;3(1):1–10.
2. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity: *Maedica*. 2013;8(1):59–67.
3. Rui Adão, Gilles de Keulenaer, Adelino Leite Moreira CB-S. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies. *Port J Cardiol*. 2013;32(5):395–409.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018 : GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68:394–424.
5. International Agency for Research on Cancer. GLOBOCAN. Estimated number of new cases in 2018, worldwide, both sexes, all ages [Internet]. 2018. Available from: <http://gco.iarc.fr/today/online-analysis-multi-bars.-> Cited October 2018.
6. Kementerian Kesehatan RI. Situasi Penyakit Kanker. *Infodatin-Kanker*. Pusat Data dan Informasi Kesehatan. 2015;hal 3.
7. Rekam Medis RSUP Dr. M. Djamil Padang. Data pasien kanker payudara 2018-2019. Padang; 2019.
8. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity. *J Am Coll Cardiol*. 2014;64(9):938–45.
9. Volkova M, Russell R. Anthracycline cardiotoxicity: Prevalence , pathogenesis and treatment. 2011;7:214–20.
10. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. *Eur Heart J*. 2016;37(36):2768–801.
11. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. *Am J Cardiol* 2015;4:617.
12. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: Where these entities intersect: a scientific statement from the American Heart Association. *Circulation*. 2018;137: 30–66.
13. Jessup M, Shaikh, Dallen V. Off target: Chemotherapeutics and cardiovascular system anthracyclines induces cardiomyopathy. *Curr Heart Failure Revision*. 2012;9:117.
14. Prima R. Korelasi nilai troponin t dan nilai fungsi diastolik menggunakan tissue doppler imaging pada pasien kanker payudara yang mendapatkan doxorubisin [Skripsi]. Universitas Andalas; 2014:35.
15. McGowan J V, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. *Cardiovasc Drugs Ther*. 2017;31:63–75.

16. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Lois M. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *J Am Medical Assoc.* 1991;266(12):1672-7.
17. Patnaik JL, Byers T, Diguseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer : a retrospective cohort study. *Breast Cancer Research.* 2011;13:1-9.
18. Schmitt K, Tulzer G, Merl M, Aichorn G, Grillenberger A WG. Early detection of doxorubisin and daunorubicin cardiotoxicity by echocardiography: Diastolic versus systolic parameters: *Eur J Pediatr.* 1995;154(3):201-4.
19. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. *Br J of Cancer.* 2002;86:1697-700.
20. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin Cardiomyopathy. *Cardiology.* 2010;115:155-62.
21. Centers for Disease Control and Prevention. What Is Breast Cancer? [Internet]. 2017. Available from: www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm. -Cited January 2019.
22. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor 767/MENKE/SK/VII/2010 tentang pedoman teknis pengendalian kanker payudara dan kanker leher rahim. Jakarta. 2017.
23. American Cancer Society. What is breast cancer? [Internet]. 2018 [cited 2018 Oct 10]. Available from: <https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html> -Cited January 2019.
24. Dorland WAN. Kamus Kedokteran Dorland. 31st ed. Jakarta: Buku Kedokteran EGC; 2010.
25. Sjamsuhidajat R, De Jong W, editors. Buku Ajar Ilmu Bedah. Sjamsuhidajat -De Jong Sistem organ dan tindak bedahnya(1). 4th. Jakarta: Penerbit Bukur Kedokteran EGC; 2010.
26. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. *CA: a cancer J Clin .* 2015;65(2):87-108.
27. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. *Cancer Biol Med.* 2014;11(2):101-15.
28. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. *The Lancet Oncology.* 2001;44(0):133-40.
29. Babu R. *Clinical Surgery Pearls* 2nd Ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013.
30. Hejmadi M. *Introduction of cancer biology.* 2010.
31. Polyak K. Science in medicine Breast cancer : origins and evolution. *J Clin Invest.* 2007;117(11):3155-63.
32. National Comprehensive Cancer Network, American Cancer Society. *Breast cancer treatment guidelines.* 2006.
33. Myal Y, Leygue E BA-JBB. Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers. *Pubmed.* 2010.
34. Rahma AB, Arafah, Notobroto HB. Faktor yang berhubungan dengan perilaku ibu rumah tangga melakukan pemeriksaan payudara sendiri

- (SADARI)[Skripsi]. Universitas Airlangga.2017:143–53.
35. Breast cancer now. What are the signs and symptoms of breast cancer? [Internet]. Available from: <https://breastcancernow.org/about-breast-cancer/want-to-know-about-breast-cancer/what-are-the-signs-and-symptoms-of-breast-cancer.-Cited November 2018>
 36. Panigoro S, Hernowo BS, Purwanto H. Kanker payudara. Kementrian Kesehatan Republik Indonesia. 2017;1–124.
 37. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017;67(4):290–303.
 38. Survival rate on breast cancer [Internet]. American Cancer Society. 2019 [cited 2019 May 8]. Available from: <https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html.-Cited May 2019>.
 39. Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevidis I. A focus on cardiotoxicity. *European Cardiology Review.* 2018;64–9.
 40. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozenzweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med.* 1979;91(5):710–7.
 41. Kumar S, Marfatia R, Tannenbaum S, Yang C, Avelar E. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. *Tex Heart Inst J.* 2012;39(3):424–7.
 42. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol.* 2012;52(6):1213–25.
 43. Cochera F, Dinca D, Bordejevic DA, Citu IM, Ador M, Tomescu MC, et al. Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. *Cancer Manag Res.* 2018;10:2071–81.
 44. Caulfield JB. Cardiac matrix alterations induced by adriamycin. *Am J Pathol.* 1988;133(2):298–305.
 45. Zaputra H. Hubungan pemakaian angiotensin converting enzym inhibitor dengan fraksi ejeksi ventrikel kiri pada pasien kanker payudara yang mendapat kemoterapi doksorubisin [Tesis]. Universitas Andalas. 2017.
 46. Gulati M, Mulvagh SL. The connection between the breast and heart in a woman: Breast cancer and cardiovascular disease. *Clin Cardiol.* 2018;41(2):253–7.
 47. Aziza Aulia I. Gambaran prevalensi dan risiko penyakit kardiovaskular pada penduduk dewasa di provinsi DKI Jakarta.[Skripsi]. Universitas Indonesia. 2011.
 48. Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the elderly. *J Clin Oncol.* 2014;32(24):2654–61.
 49. Viale PH YD. Cardiovascular toxicity associated with cancer treatment. *J Clin Oncol.* 2008;12:627–38
 50. Vo JB, Nolan TS, Vance DE, Patrician PA MK. Cardiovascular disease risk among breast cancer survivors: an evolutionary concept analysis. *PLoS Med.* 2017;7:9–16.

51. Rosano GMC, Vitale C, Marrazi G VM. Menopause and cardiovascular disease: the evidence. *Climacteric*. 2009;10(1):19–24.
52. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. *Ther Adv Vaccines*. 2017;5(2):39–47.
53. Maifitrianti, Sutandyo N, Andrajati R. Factor that affect the decline of left ventricular ejection fraction in cancer patients treated with doxorubicin at dharmais. *Media Farm*. 2015;12:233–46.
54. Rosano GMC, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus heart failure in diabetes mellitus. *Cardiac Failure Review*. 2017;3(1):52–5.
55. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 41 Tahun 2014 tentang pedoman gizi seimbang. Jakarta. 2014;21.
56. British Heart Foundation. How does smoking damage your heart? [Internet]. Available from: <https://www.bhf.org.uk/informationsupport/risk-factors/smoking>. -Cited August 2019.
57. Jayanti IGAN, Wiradnyani NK, Ariyasa IG. Hubungan pola konsumsi minuman beralkohol terhadap kejadian hipertensi pada tenaga kerja pariwisata di Kelurahan Legian. *J Gizi Indones*. 2018;6(1):65.
58. Dahlan MS. Langkah-langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan. Jakarta: Sagung Seto; 2016.
59. Oktaviana DN, Damayanthi E dan K. Faktor risiko kanker payudara pada pasien wanita di Rumah Sakit Kanker Dharmais, Jakarta. *Indones J Cancer*. 2012;6(3):105–11.
60. Sihombing M, Sapardin AN. Faktor risiko tumor payudara pada perempuan umur 25-65 tahun di lima kelurahan kecamatan Bogor Tengah. *Pus Teknol Terap Kesehat dan Epidemiol Klin*. 2014.
61. Chotimah K. Hubungan obesitas dengan kejadian kanker payudara di rumah sakit PKU Muhammadiyah Yogyakarta tahun 2010-2013 [Skripsi]. Aisyiyah Yogyakarta. 2014.
62. Prawirohardjo AN, Soewoto W, Alfianto U. Hubungan index massa tubuh dengan grading pada kanker payudara. *Biomedika*. 2018;10(1):41–5.
63. Damayanti AY, Indarto D, Wasita B, Ardyanto TD. Indeks massa tubuh, asupan vitamin D, dan serum 25-hydroxyvitamin D pada pasien kanker payudara. *J Gizi Klin Indones*. 2018;14(2):56.
64. Aruna S, Govardhana CN. A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. *J Res Pharm Pr*. 2014;3(1):12–8.
65. McPherson K, Steel CM DJ. ABC of breast diseases: breast cancer epidemiology, risk factors, and genetics. *BMJ*. 2000;321:624–8
66. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: A meta-Analysis. *Breast Cancer Res Treat*. 2010;123(3):641–9.
67. Karima UQ, Wahyono TYM. Faktor-faktor yang berhubungan dengan kejadian kanker payudara wanita di Rumah Sakit Umum Pusat Nasional (RSUPN) dr. Cipto Mangunkusumo Jakarta tahun 2013 [Skripsi]. 2013;1–20.
68. Utami SS, Mustikasari M. Aspek Psikososial Pada Penderita Kanker

- Payudara: Studi Pendahuluan. *J Keperawatan Indones*. 2017;20(2):65.
69. Hardiano R, Huda N. Gambaran indeks massa tubuh pada pasien kanker yang menjalani kemoterapi. *Jom*. 2015;2(2).
 70. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. *CANCER*. 2003;97(11):2869–79.
 71. Hershman DL, McBride RB, Eisenberger A Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity. *J Clin oncol*.2008;26(19):3159-65.
 72. Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer. *J Clin Oncol*. 2016;34(26):3157–65.

